Nuclivision, a Belgian startup specializing in software solutions for nuclear medicine, has raised €5 million from a pool of prominent investors.
The round was led by Antwerp-based Heran Partners – a VC firm with a focus on healthcare – and the Dutch VC LUMO Labs (through their €100 million Rise Fund). Flanders’ imec.istart future fund also participated in the round.
Nuclivision is the beneficiary of an ESA Spark Funding incentive to include algorithms developed for Earth Observation into their flagship product, Nuclarity. This solution improves the image quality of PET scans, thus enabling lower doses of radiotracers for the patients, while reducing the time and cost to obtain the output for hospitals and diagnostic centers.
With this new private capital,the company will be able to expand the team, refine the product and scale it across multiple geographies and new use-cases.
The founder and CEO Maarten Larmuseau (center in the picture above) commented on the news: “The support from ESA has allowed us to further refine our technology and extend the scope of our clinical validation. We see strong parallels between the technological innovations in earth observation and medical imaging and strongly believe that both fields can and should learn from each other.”
Besides the funding, Nuclivision just updated their white paper to include a recent clinical study, pointing to promising results for Nuclarity in terms of image quality and lesion detection accuracy.